Loading...
menu
Search
AI Chat
AI Strategies
Products
Markets
News
Resources
Pricing
Home
ETF
LGVN
LGVN
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
LGVN News
Longeveron Appoints New CEO Stephen H. Willard
2d ago
seekingalpha
Longeveron Appoints New CEO to Drive Growth
2d ago
Newsfilter
Pediatric Priority Review Voucher Program Reauthorized
Feb 05 2026
Newsfilter
Longeveron Secures Japanese Patent for Stem Cell Therapy Assays
Jan 29 2026
Newsfilter
Longeveron Joins JPM Healthcare Week to Focus on Alzheimer's Disease
Dec 29 2025
Globenewswire
Longeveron Joins Alzheimer's Health Moonshot Initiative During JPM Healthcare Week
Dec 29 2025
Newsfilter
Longeveron Secures Patent for Treating Female Sexual Dysfunction
Dec 17 2025
Newsfilter
Longeveron Secures Patent for Treating Female Sexual Dysfunction
Dec 17 2025
Globenewswire
Longeveron Executives to Speak at CVCT Forum on Cell Therapy Innovations
Dec 03 2025
Newsfilter
Longeveron Executives to Speak at Global CVCT Forum on Cell Therapy Innovations
Dec 03 2025
Globenewswire
Longeveron Secures Canadian Patent for Aging-Related Frailty Treatment
Dec 02 2025
Newsfilter
Longeveron Secures Canadian Patent for Aging-Related Frailty Treatment
Dec 02 2025
Globenewswire
Longeveron Reports New Advances in Alzheimer’s Stem Cell Therapy
Dec 01 2025
Globenewswire
Longeveron Reports New Advances in Alzheimer's Stem Cell Therapy
Dec 01 2025
Newsfilter
Biotech Stocks MODD, LAB, HOWL, COGT, LGVN, and ABCL Surge in After-Hours Trading - Nov 26
Nov 28 2025
NASDAQ.COM
Longeveron's Laromestrocel Findings in Alzheimer's Disease Chosen for Poster Presentation at CTAD 2025 Conference
Nov 19 2025
Newsfilter
Show More News
